Composition for delivery of genetic material
The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and an exosome isolated from a cell, wherein the exosome comprises exogenous genetic material loaded into an exosome already isolated from the cell, and the exogenous genetic material comprises a chemically modified oligonucleotide, wherein the oligonucleotide is a morpholino (PMO) or an oligonucleotide comprising at least one chemical modification selected from peptide nucleic acid (PNA), 2′O-methyl, 2′ methoxy-ethyl, phosphoramidate, methylphosphonate, and phosphorothioate.
2. A pharmaceutical composition according to claim 1 , wherein the backbone chemistry of the modified oligonucleotide is phosphorothioate.
3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and an exosome isolated from a cell, wherein the exosome comprises exogenousgenetic material loaded into an exosome already isolated from the cell, and the exogenousgenetic material comprises a chemically modified unnatural oligonucleotide, comprising at least one chemical modification selected from peptide nucleic acid (PNA), 2′O-methyl, 2′ methoxy-ethyl, phosphoramidate, methylphosphonate, and phosphorothioate, wherein the exogenousgenetic material is an antisense oligonucleotide, an RNA interference effector moiety, or a morpholino.
4. A pharmaceutical composition according to claim 3 , wherein the RNA interference effector moiety is an siRNA or shRNA.
5. A pharmaceutical composition according to claim 3 , wherein the antisense oligonucleotide, RNA interference effector moiety or morpholino induces gene silencing, trans-splicing and/or exon skipping.
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and an exosome isolated from a cell, wherein the exosome comprises exogenous genetic material loaded into an exosome already isolated from the cell, and the exogenous genetic material comprises a chemically modified oligonucleotide, wherein the exosome has been modified to comprise a targeting moiety expressed on the surface of the exosome which binds to a moiety present on a target cell, wherein the targeting moiety is expressed as a fusion protein with an exosomal transmembrane protein.
7. A pharmaceutical composition according to claim 6 , wherein the exosomal transmembrane protein is selected from Lamp-1, Lamp-2, CD13, CD86, Flotillin, Syntaxin-3, CD40, CD40L, CD44, ICAM-1, Integrin alpha4, L1CAM, LFA-1, Vti-1A, Vti-1B, CD9, CD37, CD53, CD63, CD81, CD82, CXCR4, HLA-DM (MHC II), MHC-I or MHC-II components, TCR beta or tetraspanins.
8. A method of gene silencing, inducing trans-splicing or inducing exon skipping, comprising administering to a non-human animal model or a human a pharmaceutical composition according to claim 1 , wherein the exosome is loaded with an antisense oligonucleotide directed against a target gene, an siRNA or shRNA directed against a target gene, or a morpholino directed against a target gene.
9. A method of producing a pharmaceutical composition according to claim 5 , comprising providing an exosome, and loading the exosome with genetic material by electroporation or transfection.
10. A method of treatment of a disease or condition selected from cancer, a neurodegenerative disease, myotonic dystrophy, Duchenne Muscular Dystrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischaemic stroke damage or spinal muscular atrophy, comprising administering a pharmaceutical composition according to claim 1 to a human in need thereof.
11. A pharmaceutical composition according to claim 1 , wherein the chemically modified oligonucleotide is present at a dose of at least 0.01 mg per kg of body weight of the patient to be treated.
12. The pharmaceutical composition according to claim 6 , wherein the target cell is a cell of the brain, midbrain, striatum, cortex, liver, lung, pancreas, muscle, kidney or a diseased tissue such as a tumour.
13. The pharmaceutical composition according to claim 12 , wherein the target cell is a brain cell and the targeting moiety is RVG.
14. The pharmaceutical composition according to claim 12 , wherein the target cell is a muscle cell and the targeting moiety is a muscle specific peptide.
15. The method of treatment of a disease or condition according to claim 10 , wherein the exogenous genetic material comprised in the exosome targets Ras, c-myc VEGFR-2, BACE-1, alpha-synuclein, htt, caspase-3 or DMPK.
16. The method of treatment of a disease or condition according to claim 10 , wherein the pharmaceutical composition is administered repeatedly daily, weekly, monthly, or yearly.
17. The pharmaceutical composition according to claim 5 , further comprising additional pharmaceutically active materials.
18. The pharmaceutical composition according to claim 3 , further comprising additional pharmaceutically active materials.
19. The pharmaceutical composition according to claim 6 , further comprising additional pharmaceutically active materials.
20. A method of treatment of a disease or condition selected from cancer, a neurodegenerative disease, myotonic dystrophy, Duchenne Muscular Dystrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischaemic stroke damage or spinal muscular atrophy, comprising administering a pharmaceutical composition according to claim 3 to a human in need thereof.